Scarica l'app Stockscreener
80.33
0.24%
0.16
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DXCM Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$80.17
Aprire:
$80.67
Volume 24 ore:
1.70M
Relative Volume:
0.50
Capitalizzazione di mercato:
$31.52B
Reddito:
$4.15B
Utile/perdita netta:
$535.20M
Rapporto P/E:
59.95
EPS:
1.34
Flusso di cassa netto:
$575.20M
1 W Prestazione:
+5.18%
1M Prestazione:
-3.61%
6M Prestazione:
-4.44%
1 anno Prestazione:
+13.15%
Intervallo 1D:
$80.15
$81.56
Intervallo di 1 settimana:
$75.59
$81.56
Portata 52W:
$57.52
$93.25
Dexcom Inc Stock (DXCM) Company Profile
Nome
Dexcom Inc
Settore
Industria
Telefono
(858) 200-0200
Indirizzo
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Confronta DXCM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
80.36 | 30.53B | 4.15B | 535.20M | 575.20M | 1.34 |
|
ABT
Abbott Laboratories
|
129.40 | 228.63B | 43.11B | 13.98B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
102.80 | 152.25B | 18.49B | 2.51B | 3.23B | 1.68 |
|
SYK
Stryker Corp
|
378.60 | 144.00B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
93.04 | 118.82B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.96 | 45.89B | 5.69B | 4.14B | 577.90M | 6.96 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-16 | Iniziato | Truist | Buy |
| 2025-05-30 | Iniziato | Goldman | Buy |
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-02-03 | Aggiornamento | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Iniziato | Redburn Atlantic | Neutral |
| 2024-03-12 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2023-01-26 | Iniziato | Wolfe Research | Outperform |
| 2022-10-18 | Iniziato | Barclays | Equal Weight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-15 | Iniziato | Bernstein | Outperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-02-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-01-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-18 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-28 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Overweight |
| 2021-01-06 | Aggiornamento | UBS | Neutral → Buy |
| 2020-10-02 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Reiterato | Piper Sandler | Overweight |
| 2020-05-14 | Iniziato | Wells Fargo | Equal Weight |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-11-07 | Reiterato | Canaccord Genuity | Buy |
| 2019-11-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-10-23 | Iniziato | Stifel | Buy |
| 2018-11-28 | Iniziato | UBS | Neutral |
| 2018-10-19 | Aggiornamento | Goldman | Sell → Neutral |
| 2018-09-12 | Aggiornamento | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Reiterato | Canaccord Genuity | Buy |
| 2018-07-02 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Iniziato | BofA/Merrill | Buy |
| 2018-05-03 | Reiterato | Canaccord Genuity | Buy |
| 2018-04-04 | Iniziato | Goldman | Sell |
| 2018-04-04 | Iniziato | Guggenheim | Neutral |
| 2018-03-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Downgrade | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Reiterato | Wedbush | Outperform |
Mostra tutto
Dexcom Inc Borsa (DXCM) Ultime notizie
FriskaAi and Dexcom Enter CGM Data Integration Agreement - The Joplin Globe
Saudi Arabia Blood Glucose Device Market Trends and Company Analysis Report 2025-2033 Featuring Abbott Laboratories, Medtronic, Dexcom, Braun, DarioHealth, Sanofi, Bionime, and Novo Nordisk - Yahoo Finance
5 Revealing Analyst Questions From DexCom’s Q2 Earnings Call - Yahoo Finance
DXCM Q2 CY2025 Deep Dive: Volume Growth, Leadership Changes, and New Product Launches Shape Outlook - ca.finance.yahoo.com
How much upside does DexCom Inc. haveFree Investment Webinars - thegnnews.com
Dexcom Shares Drop 1.28% on 0.33B in Volume Ranking 313th as Institutions Cut Holdings Despite Earnings Surge - AInvest
DexCom Inc. Recovery Likely Here’s What Data ShowsEntry Alert Based on Volume Spikes Detected - metal.it
Tandem, Insulet monitoring CMS payment proposal for diabetes tech - MedTech Dive
Dexcom and Apple Watch team up to 'empower Aussies living with diabetes' - iTWire
Insulet Peer Tandem Diabetes Underwhelming Earnings, Dull Outlook Drags Stock - Benzinga
Inside Dexcom’s strategy to stay ahead in the $13.6bn CGM market - Yahoo Finance
DEXCOM ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Dexcom Rises 1.25% on Strong Earnings Amid Leadership Shift $370M Trading Volume Ranks 315th - AInvest
What You Need to Know Ahead of DexCom’s Earnings Release - MSN
Stock Analysis | Dexcom OutlookMixed Signals Amid Earnings and Tariff Uncertainty - AInvest
DexCom (DXCM) Extends Losses on Day 5 Amid Leadership Change - MSN
DexCom Extends Losses Amid Leadership Change Amid Q2 Revenue Growth - AInvest
Diabetes Management App Market Is Booming So Rapidly: Dexcom, Glooko, AgaMatrix - openPR.com
Dexcom, Inc. shares rise 1.22% premarket as equity markets rebound on Fed rate cut bets. - AInvest
Global Diabetes Management Software Market Outlook 2022 - openPR.com
Day 5 of Loss Streak for DexCom Stock with -15% Return (vs. -2% YTD) [8/4/2025] - Trefis
Dexcom recall triggered by reports of speaker malfunctions - BioWorld MedTech
DexCom, Inc. (DXCM) Stock Analysis: Impressive 28.76% Upside With Strong Buy Ratings - DirectorsTalk Interviews
What are analysts’ price targets for DexCom Inc. in the next 12 monthsCapitalize on stocks with high profit margins - Jammu Links News
How volatile is DexCom Inc. stock compared to the marketCapitalize on high-yield stock opportunities - Jammu Links News
Is it the right time to buy DexCom Inc. stockCapitalize on emerging market sectors - Jammu Links News
Is DexCom Inc. stock overvalued or undervaluedExceptional portfolio growth - Jammu Links News
What analysts say about DexCom Inc. stockTriple-digit returns - Jammu Links News
What institutional investors are buying DexCom Inc. stockOverwhelming financial success - Jammu Links News
Is It Time to Buy DexCom at a Discount Before Growth Fully Materializes? - AInvest
DexCom Inc. Stock Analysis and ForecastOverwhelming profit margins - Jammu Links News
How many analysts rate DexCom Inc. as a “Buy”Fastest-growing stock picks - Jammu Links News
How does DexCom Inc. generate profit in a changing economyMaximize your portfolio’s earning potential - Jammu Links News
DexCom raises 2025 revenue guidance to $4.625B as type 2 non-insulin access expands - MSN
Does DexCom Inc. stock perform well during market downturnsInvest smarter with real-time trading signals - Jammu Links News
DexCom Receives 'Buy' Rating from Canaccord Genuity; Analyst Raises Price Target to $106 - AInvest
What is the risk reward ratio of investing in DexCom Inc. stockInvest like a pro with expert recommendations - jammulinksnews.com
Investors Hope for Bounce in DexCom Inc. After SelloffValue Investing Picks With Stability Outlined - metal.it
Dexcom Reports Strong Q2 2025 Growth and Leadership Change - MSN
DexCom (DXCM) Receives 'Buy' Rating from Canaccord Genuity | DXC - GuruFocus
Commit To Purchase DexCom At $50, Earn 6.2% Using Options - Nasdaq
DexCom, Inc. (NASDAQ:DXCM) Q2 2025 Earnings Call Transcript - Insider Monkey
Raymond James Maintains Buy Rating for Dexcom with $102 Price Target - AInvest
UBS Updates DexCom Price Target to $106, Maintains "Buy" Rating - AInvest
DexCom (DXCM) Q2 Revenue Jumps 15% - The Globe and Mail
DexCom Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Dexcom raises sales expectations, discusses G8 plans - MedTech Dive
DexCom stock price target raised to $106 from $105 at UBS - Investing.com Australia
DexCom (DXCM) Sees Target Price Upgrade Post-Quarterly Results - GuruFocus
Dexcom: Raymond James Keeps Strong Buy, PT Raised to $102 from $99. - AInvest
DexCom (DXCM) Receives a Price Target Boost from Baird - GuruFocus
Dexcom Inc Azioni (DXCM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.68%
0.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):